XF-73
From Infogalactic: the planetary knowledge core
250px | |
Identifiers | |
---|---|
718638-68-7 ![]() |
|
ChemSpider | 8094227 |
Jmol 3D model | Interactive image |
PubChem | 9918582 |
|
|
|
|
Properties | |
C44H50Cl2N6O2 | |
Molar mass | 765.82 g·mol−1 |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial which works via weakening bacteria cell walls.[1] It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.[2][3][4]
It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.[1][5]
Structurally it is a dicationic porphyrin.[6]
References
- ↑ 1.0 1.1 Promising new drug XF-73 kills superbugs within 5 minutes,[dead link] 20 Sept 2010
- ↑ Destiny Pharma - XF-73 (shows molecular structure)
- ↑ European Society of Clinical Microbiology and Infectious Diseases. XF-73, Apr 2008
- ↑ Scientists 'on brink of cure' for superbug, The Independent, 18 May 2008
- ↑ MRSA: UK scientists 'close to a treatment, The Daily Telegraph
- ↑ Destiny Pharma - XF series
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Articles with dead external links from October 2011
- Pages with broken file links
- Articles without EBI source
- Articles without KEGG source
- Articles without UNII source
- Pages using collapsible list with both background and text-align in titlestyle
- Articles containing unverified chemical infoboxes
- Antimicrobials
- Tetrapyrroles
- Pharmacology stubs